Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Mar;275(3):229-50.
doi: 10.1111/joim.12178.

Advances in the prevention of Alzheimer's disease and dementia

A Solomon  1 , F Mangialasche, E Richard, S Andrieu, D A Bennett, M Breteler, L Fratiglioni, B Hooshmand, A S Khachaturian, L S Schneider, I Skoog, M Kivipelto
Affiliations

Advances in the prevention of Alzheimer's disease and dementia

A Solomon et al. J Intern Med. 2014 Mar.

Abstract

Background: Definitions and diagnostic criteria for all medical conditions are regularly subjected to reviews and revisions as knowledge advances. In the field of Alzheimer's disease (AD) research, it has taken almost three decades for diagnostic nomenclature to undergo major re-examination. The shift towards presymptomatic and pre-dementia stages of AD has brought prevention and treatment trials much closer to each other than before.

Methods: Here we discuss: (i) the impact of diagnostic reliability on the possibilities for developing preventive strategies for AD; (ii) the scientific evidence to support moving from observation to action; (iii) ongoing intervention studies; and (iv) the methodological issues and prospects for balancing strategies for high-risk individuals with those for broad population-based prevention.

Results: The associations between neuropathology and cognition are still not entirely clear. In addition, the risk factors for AD dementia and the neuropathological hallmarks of AD may not necessarily be the same. Cognitive impairment has a clearer clinical significance and should therefore remain the main focus of prevention. Risk/protective factors for dementia/AD need to be studied from a life-course perspective. New approaches in prevention trials include enrichment strategies based on genetic risk factors or beta-amyloid biomarkers (at least four ongoing pharmacological trials), and multidomain interventions simultaneously targeting various vascular and lifestyle-related risk factors (at least three ongoing trials). Experience from prevention programmes in other chronic diseases can provide additional methodological improvements.

Conclusions: Building infrastructures for international collaborations is necessary for managing the worldwide public health problem of AD and dementia. The International Database on Aging and Dementia (IDAD) and the European Dementia Prevention Initiative (EDPI) are examples of ongoing international efforts aiming to improve the methodology of preventive studies and provide the basis for larger intervention trials.

Keywords: Alzheimer's disease; biomarkers; clinical trials; dementia; prevention.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement

I. Skoog has been on the speaker’s bureau for Takeda, Esai, Shire, Lundbeck, Jansen and Pfizer.

He has been a consultant fo Takeda.

S. Andrieu has received consulting fees or payment or institutional grant from Beaufour Ipsen Pharma SAS; Esai Inc; Pierre Fabre Laboratories; Pfizer, Eli Lilly and Company, Lundbeck Inc.; Nestle S.A.; Novartis; Roche; Servier, Janssen; Exhonit; Chiesi; Sanofi.

Figures

Fig. 1
Fig. 1
PubMed articles with prevention-related keywords, listed up to June 2013, in the field of cognitive disorders in elderly populations.
Fig. 2
Fig. 2
Scheme showing how different definitions of AD can lead to different definition of primary, secondary and tertiary prevention in AD. Definition 1, according to the National Institute of Aging-Alzheimer Association workgroup; definition 2, according to Dubois et al.[2]
Fig. 3
Fig. 3
Different characteristics can be considered when targeting preventive measures leading to the identification of different populations.
See this image and copyright information in PMC

References

    1. Mangialasche F, Kivipelto M, Solomon A, Fratiglioni L. Dementia prevention: current epidemiological evidence and future perspective. Alzheimer’s research & therapy. 2012;4:6. - PMC - PubMed
    1. Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet neurology. 2010;9:1118–27. - PubMed
    1. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet neurology. 2007;6:734–46. - PubMed
    1. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–9. - PMC - PubMed
    1. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:270–9. - PMC - PubMed

Publication types